Loading stock…

Astellas Pharma Inc. (4503) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Astellas Pharma Inc.

4503Market cap $26BPrice $14.2

Country🇯🇵Japan

SectorHealthcare

IndustryPharmaceuticals

Develops and sells prescription drugs treating cancer, urology, and immune disorders worldwide. Its overactive bladder drug Myrbetriq became a billion-dollar blockbuster, while gene therapy bets now push Astellas beyond traditional pills into cutting-edge biotech territory.

In Bastion Portfolios?

52W Return+35%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+6%5

Revenue Forecast

Rev CAGR (1y)+10%6

Rev CAGR (3y)-3%1

Rev CAGR (5y)-3%1

Earnings Forecast

EPS Growth Y+1+9%6

EPS Growth Y+2-10%3

EPS Growth Y+3-21%2

Quality

Margins

EBIT Margin21%8

Net Income Margin16%7

Free Cash Flow Margin23%9

Debt

Net Debt/EBITDA0.57

Efficiency

ROE21%8

ROA10%9

Earnings Stability55

GEAR+STRONG73

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)127

P/E Ratio (Forward 3y)184

P/BV2.16

EV Multiples

EV/EBITDA Fwd69

EV/EBIT Fwd99

Yield

Free Cash Flow Yield13.2%10

Dividend Yieldna–

Momentum

Short term

1 month return+1%8

3 month return+7%8

YTD return+11%7

Mid term

Price vs 52wHigh84%6

1 year return+41%9

Long term

3 year return+26%4

5 year return+40%5

Risk Shield

Price Risk

Beta0.67

Volatility30%7

Free Cash Flow

Free Cash Flow Margin23%9

Free Cash Flow Yield13.2%10

Quality

ROCE20%9

Earnings Stability55

Net Debt/EBITDA0.57

02Growth

Is it actually growing, and how fast?

4503Astellas Pharma

Revenue FY26$13.5B

GROWTH RATING↗

VERY WEAK10 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+10%6

Revenue, next 3Y, CAGR-3%1

Revenue, next 5Y, CAGR-3%1

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+9%6

EPS growth, FY28E-10%3

EPS growth, FY29E-21%2

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 90% of companies worldwide.

Revenue is set to shrink 3%/yr over the next 3 years, behind most of the market.3/10

Revenue grew 6%/yr over the last 3 years, but it is set to shrink 3%/yr from here.

Over five years revenue is set to shrink 3%/yr, behind 90% of companies worldwide.1/10

Earnings are set to fall along with revenue (EPS about -10%/yr vs revenue -3%/yr).

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG69 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return+7%8

YTD return+11%7

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+41%9

3-year return+26%4

5-year return+40%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 41% over the past year, but 16% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+1%), over three months (+7%) and so far this year (+11%).

WATCH

Average long-term results. Multi-year returns are middling (+26% over three years and +40% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Astellas. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

4503Astellas Pharma

Revenue FY26$13.5B

GROWTH RATING↗

VERY WEAK10 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+10%6

Revenue, next 3Y, CAGR-3%1

Revenue, next 5Y, CAGR-3%1

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+9%6

EPS growth, FY28E-10%3

EPS growth, FY29E-21%2

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Growth is the weak spot here, trailing 90% of companies worldwide.

Revenue is set to shrink 3%/yr over the next 3 years, behind most of the market.3/10

Revenue grew 6%/yr over the last 3 years, but it is set to shrink 3%/yr from here.

Over five years revenue is set to shrink 3%/yr, behind 90% of companies worldwide.1/10

Earnings are set to fall along with revenue (EPS about -10%/yr vs revenue -3%/yr).

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business heading into decline. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG69 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+1%8

3-month return+7%8

YTD return+11%7

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+41%9

3-year return+26%4

5-year return+40%5

MOMENTUM ASSESSMENT

STRENGTHS

It's up 41% over the past year, but 16% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+1%), over three months (+7%) and so far this year (+11%).

WATCH

Average long-term results. Multi-year returns are middling (+26% over three years and +40% over five), roughly average for the market.

WEAKNESSES

None flagged.

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case.

04Value

Are you paying a fair price for it?

Stop guessing on Astellas. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community